209TiP - CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
| Autor: | Jimenez Exposito, M.J., Akce, M., Alvarez, J.L.M., Assenat, E., Balart, L.A., Baron, A.D., Decaens, T., Heurgue-Berlot, A., Martin, A.O., Paik, S.W., Poulart, V., Sehbai, A.S., Shimada, M., Takemura, N., Yoon, J.-H. |
|---|---|
| Zdroj: | In Annals of Oncology November 2018 29 Supplement 9:ix65-ix65 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|